GLAXF GSK plc

NEUTRAL Impact: 3/10 6-K
Horizon immediate Filed Apr 16, 2026 Processed 1mo ago SEC 0001654954-26-003598
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
GLAXF ▼ -11.62% at T+20d
NEUTRAL call ✗ call lost -11.62% · α vs SPY -17.44% · entry $29.08 → $25.70
Next anchor: T+60d in 5w
Last close $24.66 (close Jun 8) · -15.20% from $29.08 entry
Entry anchored
Apr 16, 2026
via day open
T+1d
+1.44%
call +1.44% · α +0.23%
$29.50
settled 8w ago
T+5d
-6.43%
call -6.43% · α -7.41%
$27.21
settled 7w ago
T+20d
-11.62%
call -11.62% · α -17.44%
$25.70
settled 27d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

GSK executives and directors increased their shareholdings through dividend reinvestments in April 2026. CEO Luke Miels, CFO Julie Brown, and other senior leaders acquired ordinary shares and ADSs at prices around £21.67 and $58–$59. The transactions were automatic reinvestments under deferred bonus and pension plans, not discretionary purchases.

Actionable Insight

These are routine, non-discretionary transactions tied to dividend reinvestment plans and do not signal new confidence or strategic outlook. Traders should not interpret them as bullish indicators. Monitor for any additional discretionary purchases or sales outside of automatic plans.

Key Facts

  • CEO Luke Miels acquired 1,178 ordinary shares at £21.67 each on April 14, 2026, via dividend reinvestment in the Deferred Annual Bonus Plan.
  • CFO Julie Brown acquired 1,553 ordinary shares at £21.67 each on April 14, 2026, under the same plan.
  • Multiple executives and non-executive directors acquired ADSs on April 9 and April 14, 2026, at prices between $58.35 and $59.17.
  • Transactions occurred on the London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
  • Diana Conrad also acquired 11.357 ADSs at $58.3499 on April 13, 2026, under a pension plan.

Financial Impact

Total insider share acquisitions valued at approximately $125,000–$150,000 across all reported transactions.

insider ownershipshare count

Risk Factors

  • Misinterpretation of automatic reinvestments as positive insider sentiment.
  • Limited market impact due to small transaction sizes relative to company market cap.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003598
Document: 0001654954-26-003598-index-headers.html0001654954-26-003598
Document: 0001654954-26-003598-index.html0001654954-26-003598
Document: 0001654954-26-003598.txt0001654954-26-003598
50 reports for GLAXF
Performance horizon
42% Hit rate 5 of 12 directional calls best @ T+5▲ +7.60%Apr 1, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
Type Now
Jun 9, 2026
today
6-K
NEUTRAL ★ 1/10
awaiting T+5
Jun 9, 2026
today
6-K
BULLISH ★ 7/10
awaiting T+5
Jun 1, 2026
8d ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$24.66 (+1.69%)
Jun 1, 2026
8d ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$24.66 (+1.69%)
May 28, 2026
12d ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$24.66 (+0.33%)
May 27, 2026
13d ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$24.66 (−3.56%)
May 26, 2026
14d ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$24.66 (−3.29%)
May 26, 2026
14d ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$24.66 (−3.29%)
May 22, 2026
18d ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$24.66 (−5.15%)
May 20, 2026
20d ago
6-K
NEUTRAL ★ 2/10
$25.70 $25.57▼ −0.51%▼ −1.74%$24.66 (−4.05%)
Showing 10 of 50

US Market Status

Market Closed — Opens in 6h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access